{
    "2020-08-26": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Novartis push to expand cancer arsenal gets trial win against Pfizer drug",
                "features": {
                    "keywords": [
                        "Novartis",
                        "cancer",
                        "trial win",
                        "Pfizer"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study",
                "features": {
                    "keywords": [
                        "Novartis",
                        "STAMP inhibitor",
                        "asciminib",
                        "Phase III",
                        "chronic myeloid leukemia"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}